Cibus (CBUS) Projected to Announce Earnings on Thursday

Cibus (NASDAQ:CBUS) is anticipated to post its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to post earnings of ($0.19) per share and revenue of $1.7040 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Cibus (NASDAQ:CBUS) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.06). Cibus had a negative return on equity of 200.87% and a negative net margin of 2,366.33%.The company had revenue of $1.68 million for the quarter, compared to analysts’ expectations of $1.61 million. On average, analysts expect Cibus to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cibus Trading Up 5.5%

CBUS opened at $1.91 on Tuesday. The stock’s 50-day moving average price is $1.61 and its 200 day moving average price is $1.96. Cibus has a 12-month low of $1.09 and a 12-month high of $4.19. The firm has a market cap of $145.79 million, a price-to-earnings ratio of -0.97 and a beta of 1.61.

Institutional Investors Weigh In On Cibus

Hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its stake in Cibus by 4.7% during the fourth quarter. Geode Capital Management LLC now owns 275,180 shares of the company’s stock worth $479,000 after purchasing an additional 12,467 shares during the last quarter. Raymond James Financial Inc. increased its stake in Cibus by 31.0% in the second quarter. Raymond James Financial Inc. now owns 53,713 shares of the company’s stock valued at $74,000 after purchasing an additional 12,722 shares during the last quarter. PACK Private Wealth LLC purchased a new position in Cibus in the fourth quarter valued at approximately $27,000. Bank of America Corp DE raised its holdings in Cibus by 113.4% during the fourth quarter. Bank of America Corp DE now owns 35,536 shares of the company’s stock worth $99,000 after purchasing an additional 18,885 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in Cibus by 60.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 52,364 shares of the company’s stock worth $91,000 after purchasing an additional 19,717 shares in the last quarter. 33.81% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on CBUS shares. Weiss Ratings cut shares of Cibus from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 29th. Wall Street Zen upgraded shares of Cibus from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $9.00.

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.